Sinovac Biotech Ltd. (SVA) announces positive preliminary results from a Phase 1/2 clinical trial evaluating the safety and immunogenicity of Coronavac, its COVID-19 vaccine candidate, in healthy adults at least 60 years old.
421 volunteers aged between 60 and 89 were recruited. They received two shots of the vaccine 28 days apart.
Low, medium and high doses were well-tolerated with no vaccine-related serious adverse events reported.
The seroconversion (generation of antibodies) rate and geometric mean titers (GMT) (average level of antibodies in a group) were comparable to those observed in younger adults (aged 18-59) who participated in earlier studies. Specifically, the seroconversion rate in elderly subjects was 98.0% compared to 97.4% in younger adults. GMTs in the medium dose groups were 42.2 and 44.1, respectively.
Detailed results will be submitted for publication.
The medium dose has been selected for a Phase 3 trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.